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IMPORTANCE The development of adverse clinical outcomes in patients with psychosis has
been associated with behavioral and neuroanatomical deficits related to emotion processing.
However, the association between alterations in brain regions subserving emotion processing
and clinical outcomes remains unclear.
OBJECTIVE To examine the association between alterations in emotion processing and
regional gray matter volumes in individuals at clinical high risk (CHR) for psychosis, and the
association with subsequent clinical outcomes.
DESIGN, SETTING, AND PARTICIPANTS This naturalistic case-control studywith clinical
follow-up at 12 months was conducted from July 1, 2010, to August 31, 2016, and collected
data from 9 psychosis early detection centers (Amsterdam, Basel, Cologne, Copenhagen,
London, Melbourne, Paris, The Hague, and Vienna). Participants (213 individuals at CHR and
52 healthy controls) were enrolled in the European Network of National Schizophrenia
Networks Studying Gene-Environment Interactions (EU-GEI) project. Data were analyzed
fromOctober 1, 2018, to April 24, 2019.
MAINMEASURES ANDOUTCOMES Emotion recognitionwas assessedwith the Degraded Facial
Affect Recognition Task. Three-Tesla magnetic resonance imaging scans were acquired from
all participants, and gray matter volumewasmeasured in regions of interest (medial
prefrontal cortex, amygdala, hippocampus, and insula). Clinical outcomes at 12 months were
evaluated for transition to psychosis using the Comprehensive Assessment of At-Risk Mental
States criteria, and the level of overall functioning wasmeasured through the Global
Assessment of Functioning [GAF] scale.
RESULTS A total of 213 individuals at CHR (105women [49.3%];mean [SD] age, 22.9 [4.7]
years) and 52 healthy controls (25women [48.1%];mean [SD] age, 23.3 [4.0] years) were
included in the study at baseline. At the follow-upwithin 2 years of baseline, 44 individuals
at CHR (20.7%) had developed psychosis and 169 (79.3%) had not. Of the individuals at CHR
reinterviewedwith the GAF, 39 (30.0%) showed good overall functioning (GAF score,65),
whereas 91 (70.0%) had poor overall functioning (GAF score, <65).Within the CHR sample,
better anger recognition at baselinewas associatedwithworse functional outcome (odds ratio
[OR], 0.88; 95%CI, 0.78-0.99; P = .03). In individuals at CHRwith a good functional outcome,
positive associationswere found between anger recognition and hippocampal volume
(ze = 3.91; familywise error [FWE] P = .02) and between fear recognition andmedial prefrontal
cortex volume (z = 3.60; FWE P = .02), comparedwith participants with a poor outcome. The
onset of psychosis was not associatedwith baseline emotion recognition performance (neutral
OR, 0.93; 95%CI, 0.79-1.09; P = .37; happyOR, 1.03; 95%CI, 0.84-1.25; P = .81; fear OR, 0.98;
95%CI, 0.85-1.13; P = .77; anger OR, 1.00; 95%CI, 0.89-1.12; P = .96). No differencewas
observed in the association between performance and regional graymatter volumes in
individuals at CHRwho developed or did not develop psychosis (FWE P < .05).
CONCLUSIONS AND RELEVANCE In this study, poor functional outcome in individuals at CHR
was found to be associated with baseline abnormalities in recognizing negative emotion. This
finding has potential implications for the stratification of individuals at CHR and suggests that
interventions that target socioemotional processing may improve functional outcomes.
JAMA Psychiatry. 2020;77(2):190-200. doi:10.1001/jamapsychiatry.2019.3501
Published online November 13, 2019.
Supplemental content
Author Affiliations:Author
affiliations are listed at the end of this
article.
Group Information: Themembers of
the EU-GEI High Risk Study Group
appear at the end of the article.
Corresponding Author:Gemma
Modinos, PhD, Institute of Psychiatry,
Psychology & Neuroscience,
King’s College London, SE5 8AF
London, United Kingdom
(gemma.modinos@kcl.ac.uk).
Research
JAMAPsychiatry | Original Investigation
190 (Reprinted) jamapsychiatry.com
Downloaded From: https://jamanetwork.com/ by a Kings College London User  on 02/11/2020
P sychotic disorders are associated with socioemotionaldysfunction, which manifests as emotion perceptionand expression deficits and heightened emotional
responsivity1 and represents a relatively poor prognosis.2-4
Neuroimagingstudies inestablishedschizophrenia indicatethat
socioemotionaldysfunctionisassociatedwithfunctional5-13and
structural14-16 alterationswithin a corticolimbic circuit that in-
cludes themedial prefrontal cortex (MPFC), amygdala, hippo-
campus, and insula, consistentwithpostmortemevidence im-
plicating these regions in the disorder.17 Preclinical studies in
animal models of psychosis suggest that targeting corticolim-
bicdysregulationduring thepremorbidphasemayprevent the
emergence of schizophrenia-like features in adulthood.18,19
Humanparticipantsatclinicalhighrisk (CHR) forpsychosisalso
show deficits in emotion processing20-22 and hyperactivation
withincorticolimbic regionsduringemotional tasks23-25 thatare
qualitatively similar to those seen in patientswith schizophre-
nia. However, the association between alterations in brain
regions subserving emotion processing and clinical outcomes
in individuals at CHR for psychosis remains unclear.
The primary aim of the present studywas to examine the
association between emotion processing, gray matter vol-
ume (GMV) in brain areas implicated in emotion processing,
and clinical and functional outcomes in individuals atCHR for
psychosis.WeassessedemotionrecognitionandregionalGMVs
in individuals at CHR and healthy controls, andwe evaluated
clinical and functional outcomes in the CHR sample after 12
months of follow-up. We tested the hypothesis that in indi-
viduals at CHR, adverse clinical outcomes (the subsequent
onset of psychosis or a poor level of functioning)would be as-
sociated with abnormalities in emotion recognition (happy,
angry, fearful, and neutral faces) and decreased GMV in cor-
ticolimbic areas (MPFC, amygdala, hippocampus, and insula)
at baseline.15,26
Methods
Participants
In this case-control study, baseline neuroimaging and
emotion processing data and clinical and functional out-
comes were collected from 9 psychosis early detection cen-
ters (Amsterdam, the Netherlands; Basel, Switzerland;
Cologne, Germany; Copenhagen, Denmark; London, United
Kingdom; Melbourne, Australia; Paris, France; The Hague,
the Netherlands; and Vienna, Austria) from July 1, 2010,
to August 31, 2016, as part of the European Network
of National Schizophrenia Networks Studying Gene-
Environment Interactions (EU-GEI) project.27 The present
study included the subset of individuals from the total
EU-GEI sample (345 help-seeking individuals at CHR and
66 healthy controls) for whom both neuroimaging and
emotional processing data were available; eTable 1 in the
Supplement shows basic characteristics of individuals in
and out of the study). Ethical approval for this study was
obtained from the local research ethics committees at each
of the 9 sites. All participants provided written informed
consent.
Inclusion and Exclusion Criteria and BaselineMeasures
Whether participants met CHR criteria was assessed with
the Comprehensive Assessment of At-Risk Mental States
(CAARMS).28 Exclusion criteria were past or present diagno-
sis of psychotic disorders, past or present neurological disor-
der, substance abuse or dependence according to DSM-IV
criteria, contraindication to scanning, or estimated IQ lower
than 60. Healthy controls could notmeet the criteria for CHR
or have a reported personal or (first-degree) family history of
apsychiatricorneurologicaldisorder. IndividualswhometCHR
criteria and were being treated with antipsychotic medica-
tionwerenot excludedas longas thismedicationhadnotbeen
prescribed for a psychotic episode. Data on age, sex, race/
ethnicity, andyearsofeducationwereobtained fromtheMedi-
cal Research Council Sociodemographic Schedule.29 At base-
line, trained raters assessedparticipants using theCAARMS28
and the Global Assessment of Functioning (GAF) scale (score
range: 0-100,with thehighest score indicating superior func-
tioning and no symptoms).30 Interrater reliability was as-
sessedwithmandatoryratingofonlineCAARMSandGAFtrain-
ing videos (eMethods and eTable 2 in the Supplement).
EstimatedIQwas identifiedusingtheshortenedWechslerAdult
IntelligenceScale,31 cannabisuse (yesorno)wasassessedwith
the modified Cannabis Experiences Questionnaire,32 and
tobacco (cigarettes per day) and alcohol (drinks perweek) use
were recorded with the Composite International Diagnostic
Interview.33
Emotion Recognition Assessment, MRI,
and Clinical Follow-up
A computerized version of the Degraded Facial Affect Recog-
nition (DFAR) Task34 was used to assess emotion recognition
performance. The task included photographs of 4 different
actors (2men and 2women) portraying 4 different emotions:
angry,happy, fearful, andneutral.The taskcomprised64trials,
with 16 presentations of each of the 4 emotion categories,
shownat100%and75%intensity to increase taskdifficulty.35,36
When a facewas displayed on the computer screen, a partici-
pant indicated its emotional expression by pressing a button.
A participant’s DFAR task accuracy was computed on the ba-
sis of the total number of neutral, happy, fearful, and angry
emotions correctly recognized; higher DFAR scores indicated
Key Points
Question Is altered emotion recognition associated with adverse
clinical and functional outcomes in people at clinical high risk
for psychosis?
Findings In this case-control study of 213 individuals at clinical
high risk for psychosis and 52 healthy participants, abnormalities
in the recognition of negative emotion at baseline were associated
with neuroanatomical alterations in themedial prefrontal cortex
and hippocampus and with a low level of functioning at
a 12-month follow-up.
Meaning This study found that, in people with high risk for
developing psychosis, functional outcomes are associated with
the degree to which their emotion processing is altered.
Association of Adverse OutcomesWith Emotion Processing in Individuals at Risk for Psychosis Original Investigation Research
jamapsychiatry.com (Reprinted) JAMAPsychiatry February 2020 Volume 77, Number 2 191
Downloaded From: https://jamanetwork.com/ by a Kings College London User  on 02/11/2020
better performance. The Benton Facial Recognition Test
(BFRT)37 was used to control for the possibility that impaired
facial affect recognition was secondary to a deficit in general
facial recognition.35,36DetailsonBFRTperformanceare shown
in the eResults, eTable 3, and eFigure 1 in the Supplement.
At baseline, 3-T magnetic resonance imaging (MRI) scans
were collected from all participants and preprocessed using
voxel-based morphometry38 implemented on statistical
parametric mapping software (SPM12; GNU General Public
License). The eMethods and eFigure 2 in the Supplement pro-
vide details on MRI acquisition, quality assessment, and pre-
processing. At 12 months, the level of overall functioning was
assessedwith theGAFscale.30Changes inGAFscoresover time
were also analyzed (eResults and eFigure 3 in the Supple-
ment). Transitionornontransition topsychosiswithina2-year
periodafterbaselinewas identifiedusing theCAARMSpsycho-
sis threshold criteria (eTable 4 in the Supplement), with diag-
nosis confirmedby theStructuredClinical Interview forDSM-IV
Axis IDisorders,39administeredbyaresearcher trainedin itsuse.
Statistical Analysis
Demographic and Clinical Data
Analyses of demographic and clinical data were performed in
SPSS,version25(IBMCorp).Theassociationofgroupwiththese
measures was examined using 2-sample, unpaired, 2-tailed
t tests or χ2 tests. Effect sizes are expressed as odds ratios (OR)
and considered statistically significant at 2-sided P < .05. Data
were analyzed fromOctober 1, 2018, to April 24, 2019.
DFARData and Data Integration
Binary logistic regression examined the associations between
DFARtaskperformanceandcase-control status at baseline, ad-
justed for age, sex, IQ, site, and BFRT score.36 To find the asso-
ciationsbetweenDFARperformanceandclinicaloutcomes,we
dichotomized the CHR sample according to transition vs non-
transition to psychosis40 and in terms of good (GAF score ≥65)
vspoor(GAFscore<65)overall functioningatfollow-up.30AGAF
score of 65was chosen for consistencywith the score in previ-
ous neuroimaging studies in CHR.41,42 Binary logistic regres-
sionanalyseswereperformed(transitionvsnontransition;good
vspoor functioning)withthesamecovariates.Afterpreprocess-
ing, segmented, normalized, and smoothed GMV images were
analyzed in a group using SPM12 to find the associations with
DFAR task performance. Individual DFAR task accuracy values
wereenteredasregressors inseparatevoxelwiseanalysesofvari-
ance toexamine the interactionsbetweengroupstatus (healthy
controlsvsCHR; transitionvsnontransition;goodvspoor func-
tioning) and DFAR task performance on each emotion cat-
egory, covarying for age, sex, IQ, scanner, and BFRT score. For
the imaging analysis, the variable scanner instead of site was
used.AlthoughtheDFARtaskwasadministeredateachsite,par-
ticipants from Amsterdam and The Hague were scanned in
Amsterdam,asitethatchangedscannersduringtheEU-GEIproj-
ect (eTable 5 in the Supplement). The analyses of variance also
usedproportional scalingof the total intracranial volumetoad-
just for global effects. An initial height threshold of uncor-
rectedP < .001wasused to thenapply small volumecorrection
for region-of-interest analyses at a voxelwise height threshold
of familywise error (FWE) P < .05,43 using a prespecified bilat-
eralmask.Themaskwasderived fromtheWFU_Pitckatlas tool-
box in SPM12 and comprised a network implicated in emotion
(MPFC, amygdala, hippocampus, and insula). The MPFC and
amygdala were chosen because of their central roles in emo-
tion processing44-46 and because emotion-processing abnor-
malities in schizophrenia have been associated with volumet-
ricalterations intheseregions.10,12,15,24,47Thehippocampuswas
selected because of its key role in the onset of psychosis in pre-
clinical models48 and volumetric decreases in this region in
individualsatCHRwhotransitiontopsychosis.49Theinsulawas
chosenbecauseof its involvementinemotionprocessing50,51and
its role in facial emotion recognition in individuals at CHR.21
Potential confounding effects of antipsychotic or antide-
pressantmedication (yes or no), substance use (tobacco, can-
nabis, or alcohol), or baseline levels of CAARMSanxiety or de-
pression symptom severity on regions showing statistically
significant DFAR-GMV interactions were assessed in SPSS
(antidepressants, substances, andCAARMSanxietyordepres-
sion) or SPM (antipsychotic drugs) (eResults in the Supple-
ment). Because our hypotheses involved the association be-
tween DFAR-GMV interactions with clinical outcomes, only
participants for whom these data were available were in-
cluded in thepresent study.Groupdifferences inGMVare cur-
rently under analysis (M. J. Kempton, PhD, unpublisheddata,
2019). Analysis of DFAR task performance andGMVby site or
scanner is shown in eTable 6 in the Supplement. Sensitivity
analysesdata are reported in theeResults, eTables 7 and8, and
eFigures 4 and 5 in the Supplement.
Results
Demographic and Clinical Data
At baseline, the participantswhohadMRI andDFARdata and
thereforewere included in the studywere213help-seeking in-
dividuals atCHRforpsychosis (105women[49.3%];mean [SD]
age, 22.9 [4.7] years) and 52 healthy controls (25 women
[48.1%]; mean [SD] age, 23.3 [4.0] years) (Table 1). Of the 213
individuals at CHR, 193 (90.6%) were naive to antipsychotic
medication, and the remaining 20 (9.4%) were receiving low
doses of antipsychotics (<1.5 mg haloperidol chlorpromazine
equivalents per day). TheCHRandhealthy control groupsdid
not differ statistically significantly in age (t = 0.596; P = .55),
sex (χ2 = 0.025; P = .88), race/ethnicity (χ2 = 9.023; P = .11),
BFRTscore (t = –0.005;P = .99), cigarettes (t = –1.913;P = .06),
alcohol (t = –0.304; P = .76), or cannabis (χ2 = 0.403; P = .53)
use. However, individuals at CHR had fewer years of educa-
tion (t = 3.639; P < .001) and lower IQ (t = 5.051; P < .001).
Clinical Outcomes and Facial Emotional Processing
After 12months, 39 of the 130 individuals (30.0%) at CHR re-
interviewedwith theGAFat follow-uphad goodoverall func-
tioning (CHR-GO), whereas 91 (70.0%) had poor overall func-
tioning (CHR-PO). No significant differences at baselinewere
observed in any clinical or demographic measures between
these subgroups (Table 1).Within the2years after baseline, 44
individuals at CHR (20.7%) had developed a first episode of
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psychosis or transitioned (CHR-T). Themean (SD) time to tran-
sition in the CHR-T group was 296.3 (257.6) days. Among in-
dividuals atCHR, 169 (79.3%)didnotdeveloppsychosiswithin
thisperiod,ornontransitioned (CHR-NT).Atbaseline, theonly
significant difference in clinical or demographicmeasures be-
tween the CHR-NT and the CHR-T subgroups was that the
CHR-Tgrouphad ahigherBFRT score (t = –2.470;P = .01) and
included more individuals receiving low doses of antipsy-
chotic medications (χ2 = 15.028; P < .001) (Table 1). The dis-
tributionof individuals in theCHR-NTorCHR-Tgroupsamong
the CHR-GO and CHR-PO follow-up groups is shown in eFig-
ure 6 in the Supplement.
Atbaseline,DFARtaskaccuracydidnotdiffer for anyemo-
tion between the healthy control and the total CHR groups
independent of outcomes (Table 2 and Figure 1A). However,
within the CHR sample, anger recognition at baseline was
significantly associated with the level of functioning at
12-month follow-up; anger recognition was abnormal in the
Table 1. Baseline Demographic, Clinical, andMedication Characteristics of Participants
Measure
HC
Group
(n = 52)
CHR
Group
(n = 213) P Value
CHR-NT
Group
(n = 169)
CHR-T
Group
(n = 44) P Value
CHR-GO
Group
(n = 39)
CHR-PO
Group
(n = 91) P Value
Age, mean (SD), y 23.3 (4.0) 22.9 (4.7) .55 23.0 (4.7) 22.6 (4.7) .59 23.5 (4.7) 23.1 (5.0) .66
Sex, No.
Male 27 108
.88
83 25
.36
20 50
.70
Female 25 105 86 19 19 41
Years of education, mean (SD) 16.3 (2.9) 14.6 (3.1) <.001 14.7 (3.1) 14.3 (3.0) .53 15.5 (2.8) 15.0 (3.2) .42
Race/ethnicity (% white), % 65.4 72.8 .11 72.8 72.7 .98 71.8 76.9 .41
CAARMS score, mean (SD)
Positive 0.7 (1.6) 9.9 (4.2) <.001 9.8 (4.4) 10.6 (3.6) .24 9.7 (4.5) 10.3 (4.1) .46
Negative 0.8 (1.7) 7.2 (3.4) <.001 7.1 (3.5) 7.3 (3.4) .72 7.3 (3.5) 7.6 (3.2) .70
Anxiety 0.6 (1.1) 3.1 (1.6) <.001 3.1 (1.6) 3.2 (1.6) .84 3.1 (1.6) 3.2 (1.5) .86
Depression 0.4 (0.9) 3.4 (1.3) <.001 3.4 (1.3) 3.5 (1.4) .62 3.3 (1.1) 3.5 (1.2) .41
Baseline GAF score, mean (SD) 87.2 (9.1) 54.0 (10.0) <.001 53.7 (9.6) 55.3 (11.6) .41 53.8 (8.7) 54.2 (11.1) .86
Antipsychotic drugs, No.
Total 52 167
NA
131 36
<.001
31 72
.12No 52 147 122 25 30 62
Yes 0 20 9 11 1 10
Antidepressants, No.
Total 52 167
NA
131 36
.70
31 72
.23No 52 102 79 23 22 42
Yes 0 65 52 13 9 30
Psychological treatment, No.a
Total 51 193
<.001
153 40
.04
33 85
.77No 47 117 87 30 20 49
Yes 4 76 66 10 13 36
Total intracranial volume,
mean (SD), mm3
1 493 654.5
(178 968.1)
1 493 871.5
(180 458.9)
.99 1 498 994.0
(178 703.8)
1 474 196.6
(187 846.8)
.42 1543 165.2
(169 397.6)
1 492 014.2
(192 273.4)
.15
BFRT score, mean (SD) 22.3 (2.3) 22.3 (2.2) .99 22.2 (2.2) 23.1 (1.8) .01 22.3 (2.1) 22.3 (2.3) .99
Abbreviations: BFRT, Benton Facial Recognition Test; CAARMS, Comprehensive
Assessment of At-Risk Mental States; CHR, clinical high risk; CHR-GO, clinical
high risk with good overall functioning (GAF65); CHR-NT, clinical high
risk–nontransitioned; CHR-PO, clinical high risk with poor overall functioning
(GAF <65); CHR-T, clinical high risk–transitioned; DFAR, Degraded Facial
Affect Recognition; GAF, Global Assessment of Functioning scale (score range:
0-100, with the highest score indicating superior functioning and
no symptoms); HC, healthy controls; MRI, magnetic resonance imaging;
NA, not applicable.
a Psychological treatment included counseling sessions, cognitive behavioral
therapy, family therapy, psychoeducation, or other form of therapy.
Table 2. Group Differences in Facial Emotion Recognitiona
DFAR Task
HC Group (n = 52)
vs CHR Group (n = 213)
CHR-GO Group (n = 39)
vs CHR-PO Group (n = 91)
CHR-NT Group (n = 169)
vs CHR-T Group (n = 44)
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Neutral 1.02 (0.86-1.21) .82 1.03 (0.85-1.24) .77 0.93 (0.79-1.09) .37
Happy 1.01 (0.83-1.23) .91 0.96 (0.76-1.21) .70 1.03 (0.84-1.25) .81
Fear 0.89 (0.77-1.02) .10 1.13 (0.96-1.32) .13 0.98 (0.85-1.13) .77
Anger 1.08 (0.96-1.22) .22 0.88 (0.78-0.99) .03 1.00 (0.89-1.12) .96
Abbreviations: CHR, clinical high risk; CHR-GO, clinical high risk with good
overall functioning (GAF65); CHR-NT, clinical high risk–nontransitioned;
CHR-PO, clinical high risk with poor overall functioning (GAF <65);
CHR-T, clinical high risk–transitioned; DFAR, Degraded Facial Affect Recognition;
GAF, Global Assessment of Functioning scale; HC, healthy controls;
OR, odds ratio.
a Adjusted for age, sex, IQ, site, and general facial recognition.
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CHR-PO group compared with the CHR-GO group (OR, 0.88;
95%CI, 0.78-0.99; P = .03; Table 2 and Figure 1B). No signifi-
cant associationswereobservedwithCHR-NTandCHR-Tout-
comes (Table 2 andFigure 1C). See eTable9 in the Supplement
for analysis of potential confounders.
DFAR and GMVData Integration
At baseline, a significant group × DFAR happy × GMV inter-
action was observed in the left MPFC (x, y, z = –12, 54, 0;
z = 4.01; FWE P = .03). In healthy controls, a negative corre-
lation between the recognition of happiness and MPFC vol-
ume was found, which was absent in the CHR sample
(Figure 2A). Similarly, a significant group × GMV interaction
in the MPFC for DFAR anger was observed (x, y, z = 0, 60, 18;
z = 3.83; FWE P = .049), reflecting a positive correlation be-
tween the recognition of anger and GMV in the MPFC among
healthy controls that was absent in individuals at CHR
(Figure 2B). No other significant interactions with neutral or
fearful emotion were found.
Functional Outcome and Transition to Psychosis
Subdivision of theCHR sample according to level of function-
ingat follow-uprevealed thatparticipants in theCHR-GOgroup
showed apositive association between anger recognition and
left hippocampal volume (x, y, z = −32, −40, −3; z = 3.91; FWE
P = .02) and between fear recognition and left MPFC volume
(x,y, z = −12, 38, –9; z = 3.60;FWEP = .02), comparedwithpar-
ticipants in the CHR-PO group (Figure 3). No other significant
group interactions with neutral or happy emotion were ob-
served.Nosignificantgroup × DFAR × GMVinteractionsbased
on transition vs nontransition outcomes were found. Analy-
sis of the potential confounders on all DFAR × GMV interac-
tiondata (atbaselineandfollow-up) renderedtheresults largely
unchanged (eResults; eTable 10; andeFigures 7, 8, and9 in the
Supplement).
The onset of psychosis was not associated with baseline
emotion recognition performance (neutral OR, 0.93; 95% CI,
0.79-1.09;P = .37;happyOR,1.03;95%CI,0.84-1.25;P = .81; fear
OR,0.98;95%CI,0.85-1.13;P = .77;angerOR,1.00;95%CI,0.89-
1.12;P = .96).Nodifferencewasobserved in theassociationbe-
tween performance and regional GMVs in individuals at CHR
who developed or did not develop psychosis (FWE P < .05).
Discussion
To our knowledge, this case-control study is the first to as-
sess the association between alterations in emotion process-
ing andclinical and functional outcomes in individuals atCHR
forpsychosis.Westudieda largesampleofparticipantsatCHR,
most ofwhomwerenot taking antipsychotic drugs. Themain
findingwas that, in individuals at CHR, a poor functional out-
come was associated with baseline abnormalities in both the
recognition of angry emotion and inGMV in brain regions im-
plicated in the processing of anger and fear. More specifi-
cally, comparedwith individualsatCHRwithpooroverall func-
tioning, individuals at CHR with a good functional outcome
showed a statistically significant positive association be-
tween anger recognition and hippocampal volume as well as
between fear recognition andMPFC volume. No associations
were foundbetween alterations in emotional processing or in
brain regions implicated in emotional processing and the sub-
sequent onset of psychosis in individuals at CHR.However, in
healthy controls at baseline, emotion recognition (eg, happy
Figure 1. Group Differences in Emotion Recognition
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A, The healthy control (HC) group comprised 52 participants, and the
clinical high risk (CHR) group comprised 213 participants. B, The CHRwith
good overall functioning (CHR-GO) group comprised 39 participants, and the
CHRwith poor overall functioning (CHR-PO) group comprised 91 participants.
C, The CHR–nontransitioned (CHR-NT) group comprised 169 outcomes,
and the CHR–transitioned (CHR-T) group comprised 44 outcomes. The
group differences were adjusted for age, sex, IQ, site, and general facial
recognition. The horizontal line in each box represents themedian;
top and bottom box borders, 75th and 25th percentiles, respectively;
whiskers, 90th and 10th percentiles; white circles, out values; and
black circles, far out values.
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or angry)was significantly associatedwithMPFCvolume, and
these associationswere absent in theCHRsample. These find-
ings were observed after adjusting for age, sex, scanner, IQ,
andBFRTscore and remained largelyunchangedafter remov-
ingparticipantsatCHRtaking lowdosesofantipsychoticmedi-
cations, as well as when examining potential effects of anti-
depressants or substance use. Overall, these findings suggest
that emotionaldysfunctionand relatedbrain regionsmayplay
a role in the development of adverse functional outcomes in
individuals at increased risk for psychosis.
Consistent with the main hypothesis is the finding
that, in individuals at CHR, a low level of overall functioning
at follow-up was associated with baseline alterations in
the recognition of angry emotion and decreased anger- and
fear-related hippocampal and MPFC volume. Aberrant
emotion recognition is a robust factor in poor social52 and
functional53 outcomes in patients with schizophrenia.
The hippocampus plays a key role in the pathophysiological
process of schizophrenia,54 but the clinical and functional
importance of changes in this region is still unclear.55 Abnor-
mal hippocampal volume has been associated with lower
global functioning in both schizophrenia56,57 and first-
episode psychosis.58 In CHR samples, poor functional out-
comes have been associated with increased hippocampal
glutamate levels,42 increased resting hippocampal
perfusion,59 and altered hippocampal activation.41
Decreased MPFC volume has been associated with altered
emotional processing in patients with schizophrenia com-
pared with healthy controls.15,16,26 In terms of specific emo-
tions, smaller prefrontal volumes have been associated with
worse recognition of angry emotion in a large sample of
patients with schizophrenia, a finding consistent with ours
in the CHR-PO group, which found anger as the only DFAR
task impairment in patients after adjusting for age, sex, esti-
mated IQ, and BFRT score.26 Furthermore, a recent study
using machine learning in individuals at CHR found that
baseline MFPC and temporo-parieto-occipital volume reduc-
tions were factors in socio-occupational impairments at
follow-up.60 By linking abnormalities in emotion recognition
and emotion-related brain regions to adverse functional out-
comes in individuals at CHR, the present study provides fur-
ther support for the notion that the pathophysiological pro-
cess of CHR states for psychosis involves emotion-related
regions.14 These findings may inform the development of
Figure 2. Baseline Associations Between Emotion Recognition (DFAR), GrayMatter Volume (GMV), and Group Status
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The healthy control (HC; blue) group comprised 52 participants, and the clinical
high risk (CHR; orange) group comprised 213 participants. Baseline associations
were adjusted for age, sex, IQ, scanner, and general facial recognition
(familywise error P < .05). MPFC indicates medial prefrontal cortex;
DFAR, degraded facial affect recognition. Orangemarks are the statistical
parametric maps of the interactions between GMV, DFAR performance, and
group overlaid on a standard T1 template in MRICron software (NITRC).
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new treatments for individuals at CHR, most of whom have
deficits in social and role functioning that persist after first
presentation.61,62
Thesubsequentonsetofpsychosiswasnotassociatedwith
abnormalities in either emotion recognition or emotion-
related brain regions. This findingwas unexpected given that
impaired facial emotion recognition has been reported in
patients with established schizophrenia63,64 and first-
episodepsychosis,35,65,66 andapreviousstudy inat-riskyouths
reported that lower baseline emotion recognitionwas associ-
ated with psychosis transition.67 Nevertheless, these find-
ings are in line with those from another large study of indi-
viduals at CHR,which foundno association betweenbaseline
emotion recognitionand the subsequentonset of psychosis,68
and with recent meta-analytic evidence that social cognitive
deficits are not associated with the subsequent transition to
psychosis.69 Divergent results may reflect differences in the
mean age of the participants and in sample size of the respec-
tive studies (23 years in the present study [n = 213], 16 years
in Allott et al67 [n = 37], and 20 years in Addington et al68
[n = 172]). Anotherpotential factor is limited statistical power.
Evenwith relatively large CHR samples, the size of the CHR-T
subgroupmaybesmall becauseonly someparticipantswill de-
veloppsychosis. This small sizemaybe lessof aproblemwhen
outcome is defined by level of functioning, as the numbers of
participants in subgroupswith good and poor functional out-
comesmay bemore similar. Results of the present study sug-
gest that alteredemotionprocessingmaypredispose individu-
als at CHR to poor functional outcomes through interactions
with prefronto-hippocampal anatomy.
Another findingwas that theDFAR-GMVanalysis revealed
significant differences between the healthy control group and
the total CHR group at baseline independent of outcomes.
Within healthy controls, MPFC volume was negatively
associated with happy emotion recognition, whereas anger
recognitionwas positively associatedwithMPFC volume (and
insula volume after removing participants taking antipsy-
choticmedications); theseassociationswereabsent in theCHR
sample. Broadly, these findings alignwith reports that GMV in
atopographicallysimilarMPFCregionwasassociatedwithdefi-
cits in social cognitive and emotional tasks in patients with
established schizophrenia.15,16,26 This ventral portion of the
MPFC is involved in monitoring internal affective states and
regulates the influence of those states on behavior.44 The di-
vergent directionality of the observedDFAR-GMVcorrelations
in healthy controls (negative for happiness, and positive for
anger) is interesting and merits further investigation. It may
relate to different requirements for prefrontal involvement
as a function of emotional valence and its associated
emotion regulation requirement or goal.70 Because no
further significant associations were observed with this
a priori region-of-interest analysis or in the complementary
Figure 3. Associations Between 12-Month Functional Outcomes, GrayMatter Volume (GMV), and Degraded Facial Affect Recognition (DFAR)
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The clinical high risk with good overall functioning (CHR-GO; blue) group
comprised 39 participants, and the clinical high risk with poor overall
functioning (CHR-PO; orange) group comprised 91 participants. Associations
adjusted for age, sex, IQ, scanner, and general facial recognition (familywise
error P < .05). Blue marks are the statistical parametric maps of the interactions
between GMV, DFAR performance, and group overlaid on a standard T1
template in MRICron software (NITRC).
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whole-brain analysis, these results indicate that the promi-
nent role of theMPFC in emotion recognitionmay be compro-
mised in the CHR state.
Contrary to our expectations, we found no significant
associations between amygdala volumes and DFAR perfor-
mancebetweenthebaselinegroupsor inassociationwithclini-
cal or functional outcomes. The amygdala plays a key role in
emotional processing,46 and evidence for abnormal amyg-
dala reactivity has been provided by several functional MRI
studies that used emotion processing tasks in patients with
schizophrenia.10,11However, because the alteredamygdala re-
sponse in schizophrenia is primarily evident during implicit
emotion paradigms,12 the lack of association in this study
maybe attributed to theuseof anexplicit test (DFAR task) and
mayalignwithpreviousnegative findingswith theDFAR task
by being associatedwith amygdala volumes in a large sample
of patients with schizophrenia.26 Future studies examining
implicit and explicit emotion processing in CHR samples are
needed to expand on this possibility.
Limitations
The present study has limitations. It assessed functional
outcomes in the CHR sample at 12 months and transition or
nontransition outcomes within 2 years from baseline.
Although most transitions to psychosis seem to occur in this
period,71 a median duration of the prodromal phase of 64
months has been reported72; during a longer follow-up
period, additional transitions may have been detected,
which could have altered the results. Although a 20%
transition rate provides reasonable power, and transition or
nontransition outcomes were recorded for all participants
at CHR at follow-up, the sample size may still be limited
to detect an effect associated with transition. The GAF
scale was used to index global functioning, which takes
into account current symptom severity and level of
functioning.73 Nevertheless, complementary analyses of
functional outcomes adjusted for psychosis transition
outcomes left the results of DFAR task performance and
DFAR-GMV associations unchanged, suggesting that GAF
scores captured a unique component of outcome beyond
psychosis alone. Although combining multicenter data sets
increases sensitivity, the application of voxel-based mor-
phometry to large-scale investigations pooling neuroimaging
data across sites has some potential limitations. We used the
scanner as a covariate to mitigate against the introduction of
between-center sources of variability to the data related to,
for example, imaging hardware, because of evidence that this
approach can suppress scanner effects even when the ratio of
cases to controls was unbalanced across sites.74 However,
recently developed methods such as ComBat (a popular
method in genomics for combatting batch effects when com-
bining batches of gene expression microarray data) appear to
be successful at harmonizing cortical thickness measure-
ments obtained from multiple sites75 and should be consid-
ered in future large-scale collaborative imaging studies.
Conclusions
This case-control study found that poor functional outcome
in individuals at CHR of psychosis was associated with base-
lineabnormalities in the recognitionofangryemotionandwith
abnormal associations between anger and fear emotion rec-
ognitionandbetweenhippocampal andMPFCvolumes.These
findings have potential implications for the stratification of
individualsatCHRaccording tosubsequentoutcomesandsug-
gest that functional outcomesmightbe improvedby interven-
tions that target socioemotional processing.
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